Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease.
OBJECTIVE
To assess the effectiveness of single-agent chemotherapy in the treatment of nonmetastatic and low-risk metastatic gestational trophoblastic tumors.


METHODS
The medical literature was reviewed concerning single-agent chemotherapy in the treatment of nonmetastatic and low-risk metastatic gestational trophoblastic tumors.


RESULTS
Methotrexate and actinomycin-D have achieved excellent and comparable remission rates with acceptable levels of toxicity.


CONCLUSIONS
The optimal single-agent chemotherapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors has not yet been identified and can be best determined through a prospective, randomized trial.
Homesley
H D
HD
Department of Obstetrics and Gynecology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA. homesley@nr.infininet.net
D000328:Adult; D000367:Age Factors; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003609:Dactinomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011379:Prognosis; D014328:Trophoblastic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014463:Ultrasonography; D014594:Uterine Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014944:World Health Organization
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D003609:Dactinomycin; D008727:Methotrexate